Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.

ABSTRACT:

Background

Rapid advances in scientific research have led to an increase in public awareness of genetic testing and pharmacogenetics. Direct-to-consumer (DTC) genetic testing companies, such as 23andMe, allow consumers to access their genetic information directly through an online service without the involvement of healthcare professionals. Here, we evaluate the clinical relevance of pharmacogenetic tests reported by 23andMe in their UK tests.

Methods

The research papers listed under each 23andMe report were evaluated, extracting information on effect size, sample size and ethnicity. A wider literature search was performed to provide a fuller assessment of the pharmacogenetic test and variants were matched to FDA recommendations. Additional evidence from CPIC guidelines, Pha

SUBMITTER: Lu M 

PROVIDER: S-EPMC5477417 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature